Clinical Significance of Lung Microbiota and Experience of the Inhaled Antibacterial Therapy in Children of the Omsk Cystic Fibrosis Center (Сase Series)

A growth of antibiotic-resistant Pseudomonas aeruginosa from patients with cystic fibrosis decreases a lung function significantly, which requires searching new, up-to-date antibiotics. Goal. An investigation of clinical and microbiological features of respiratory lesion and an assessment of elimination therapy at chronic P. aeruginosa infection in children on the example of the Regional Cystic Fibrosis Center. Materials and methods. A retrospective analysis of case histories of children at the Omsk Cystic Fibrosis Center (n=48) was performed, with evaluation of clinical and functional parameters depending on age and microbiological status of respiratory airways. The comparative evaluation of two drugs inhaled tobramycin Bramitob and Tobramycin-Gobbi efficiency was performed. Results. An association of microorganisms was identified from the majority of bacterial cultures of cystic fibrosis patients’ sputum (66.7%). Staphylococcus aureus (18.9%) and P. aeruginosa (16.6%) with the significant prevalence of non-mucoid forms were in the lead at the group of clinically relevant pathogens. From 2011 to 2016 amount of P. aeruginosa strains, which were sensitive to the all usable antibiotics, decreased, an especially significant decline of sensitivity was registered to amikacin (32.7%) and сiprofloxacin (48.6%). Children infected with P. aeruginosa had a lot more deviations of lung function measured by the computed bronchophonography and spirometry, they more often had changes in chest computed tomography than patients free of P. aeruginosa infection. Change from inhaled tobramycin Bramitob into inhaled tobramycin Tobramycin-Gobbi in the patients’ treatment didn’t lead to the elevation of respiratory syndrome exacerbation rates, didn’t increase requirement in the intravenous antibacterial treatment and didn’t influence to the rank of microbial colonization of sputum. Conclusion. In length of time, the increase of P. aeruginosa resistance to antipseudomonal antibiotics is observed, which makes reasonable the introduction high-concentrated forms of antibiotics. The replacement of inhaled tobramycin from Bramitob to Tobramycin-Gobbi didn’t cause the impairment of patients’ clinical and functional condition and didn’t change the microbiological status.

1. Kashirskaya NYu, Kapranov NI, Kondrat’eva EI. Porazhenie bronkholegochnoi sistemy pri mukovistsidoze. In: Orfannye zabolevaniya legkikh u detei. Ed by Rozinova N.N., Mizernitskii Yu.L. Moscow: Medpraktika-M. 2015. pp. 124–146. (In Russ).

2. Mukovistsidoz: opredelenie, diagnosticheskie kriterii, terapiya. Natsional’nyi konsensus. Moscоw; 2016. (In Russ).

3. Gorinova YuV, Simonova OI. Modern opportunities for controlling pseudomonas infection under cystic fibrosis. Effektivnaya farmakoterapiya. 2015;(3):38–45. (In Russ).

4. Shaginyan IA, Chernukha MYu. Epidemiologiya khronicheskoi infektsii legkikh u bol’nykh mukovistsidozom. In: Cystic fibrosis (Mucoviscidosis). Ed by Kapranov N.I., Kashirskaya N.Yu. Moscow: Medpraktika-M; 2014. pp. 108–116. (In Russ).

5. Kapranov NI. Pharmacotherapy of cystic fibrosis: inhaled antibiotics. Meditsinskii sovet. 2013;(11):62–69. (In Russ).

6. Kondrat’eva EI, Loshkova EV, Chernukha MYu, Shaginyan IA. Pseudomonas infection in childhood: current state of the problem. Pediatriia. 2016;95(4):187–197. (In Russ).

7. Lazareva AV, Tchebotar’ IV, Kryzhanovskaya OA, et al. P. aeruginosa: pathogenicity, pathogenesis and diseases. Clinical microbiology and antimicrobial chemotherapy. 2015;17(3):170–186. (In Russ).

8. Chebotar’ IV, Lazareva AV, Masalov YK, et al. Acinetobacter: microbiological, pathogenetic and resistant properties. Annals of the Russian academy of medical sciences. 2014;69(9–10):39–50. (In Russ).] doi: 10.15690/vramn.v69i9-10.1130.

9. Pavlinova EB, Breil’ AP, Safonova TI, Yurovsky SG. Clinical and pharmacoeconomical efficiency of cefoperazone + sulbactam in children, suffering from cystic fibrosis. Pediatric pharmacology. 2006;3(5):6–8. (In Russ).

10. Tarasova OV. Ventilyatsionnaya funktsiya legkikh u detei, bol’nykh mukovistsidozom, na sovremennom etape. [dissertation] Moscow; 2014. 108 p. (In Russ).